Skip to main
ARGX

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 53%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

argenx is a well-established Dutch biopharmaceutical company with a successful track record of bringing innovative treatments, such as Vyvgart and Vyvgart Hytrulo, to market for rare autoimmune diseases. With FDA approvals for both products and positive trial results for Empasiprubart, argenx is expected to see strong sales and continue to expand its pipeline for potential treatments in various rare diseases. Although there are risks and uncertainties, the company's solid financials and positive outlook from doctors make it a promising investment option.

Bears say

argenx is experiencing strong market growth due to the approval and commercial success of their lead product, Vyvgart, in the treatment of gMG and CIDP. However, there are concerns about the sustainability of this growth, as the company faces challenges such as potential gross-to-net impacts and potential competition in the future. The success of upcoming pipeline products, such as empasiprubart, will also be crucial in maintaining this growth trajectory.

argenx (ARGX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 53% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 17 analysts, argenx (ARGX) has a Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,144.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,144.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.